ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Intra-Cellular Therapies Announces Positive Results from Bipolar Depression Treatment Study
September 14, 2020Intra-Cellular Therapies announced positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or ... -
Intra-Cellular Therapies Provides Lumateperone Regulatory Update
September 16, 2019Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders ... -
Intra-Cellular Therapies Announces Positive Phase III Results
July 17, 2019Lumateperone achieves topline results in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.
Pharma Sources Insight January 2025
